IPP Bureau

CARE Hospitals hosts insurance summit to strengthen trust in healthcare
CARE Hospitals hosts insurance summit to strengthen trust in healthcare

By IPP Bureau - December 22, 2025

Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust

Care ADHD opens its first Global Capability Centre in India
Care ADHD opens its first Global Capability Centre in India

By IPP Bureau - December 22, 2025

UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country

Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial
Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial

By IPP Bureau - December 22, 2025

The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile

Ipsen’s FALKON trial falls short in rare FOP study, offers key insights
Ipsen’s FALKON trial falls short in rare FOP study, offers key insights

By IPP Bureau - December 22, 2025

FOP is a rare genetic disorder caused by mutations in the ALK2 kinase

Xeureka & UBE launch joint cancer drug discovery program
Xeureka & UBE launch joint cancer drug discovery program

By IPP Bureau - December 22, 2025

Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress

Sai Life Sciences unveils 2024–25 sustainability report
Sai Life Sciences unveils 2024–25 sustainability report

By IPP Bureau - December 22, 2025

The company also reported significant progress toward its internally defined Sustainable Development Goals

MARAbio launches first blood test to detect maternal autoantibody-linked autism
MARAbio launches first blood test to detect maternal autoantibody-linked autism

By IPP Bureau - December 22, 2025

The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water

Abbott wins FDA & CE nod for groundbreaking premature infant heart device
Abbott wins FDA & CE nod for groundbreaking premature infant heart device

By IPP Bureau - December 22, 2025

The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds

UK to get groundbreaking early detection test for bowel cancer
UK to get groundbreaking early detection test for bowel cancer

By IPP Bureau - December 22, 2025

Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status

GSK strikes deal with US to lower prescription drug costs & boost respiratory medicine access
GSK strikes deal with US to lower prescription drug costs & boost respiratory medicine access

By IPP Bureau - December 22, 2025

GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%

Emcure Pharma launches weight loss drug Poviztra in India
Emcure Pharma launches weight loss drug Poviztra in India

By IPP Bureau - December 22, 2025

Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management

CORONA Remedies commissions additional capacity
CORONA Remedies commissions additional capacity

By IPP Bureau - December 22, 2025

The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility

KIMS inks land agreement with Andhra Mahila Sabha to set up Rs. 300 crore hospital in Chennai
KIMS inks land agreement with Andhra Mahila Sabha to set up Rs. 300 crore hospital in Chennai

By IPP Bureau - December 22, 2025

The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025

Granules receives FDA tentative approval for generic Amphetamine ER orally disintegrating tablets
Granules receives FDA tentative approval for generic Amphetamine ER orally disintegrating tablets

By IPP Bureau - December 22, 2025

Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia

Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million
Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million

By IPP Bureau - December 22, 2025

Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs

Latest Stories

Interviews

Packaging